Angel Kennedy

Angel Kennedy

Auto-generated profile, based on publicly available information

Angel Kennedy

Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Closed access
PDF file
DRDale Roach
Dale Roach
LHLois Holloway
Lois Holloway
MJMichael G Jameson
Michael G Jameson
JDJason Dowling
Jason Dowling
AKAngel Kennedy
Angel Kennedy
MEMartin Andrew Ebert
Martin Andrew Ebert

29 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EHEmily J. Her
Emily J. Her
AHAnnette Haworth
Annette Haworth
YSYu Sun
Yu Sun
SWScott Williams
Scott Williams
HRHayley M. Reynolds
Hayley M. Reynolds
MEMartin Andrew Ebert
Martin Andrew Ebert
Purpose: Hypoxia has been linked to radioresistance. Strategies to safely dose escalate dominant intraprostatic lesions have shown promising results, but further dose escalation to overcome the effects of hypoxia require a novel approach to constrain the dose in normal tissue.to safe levels. In this study, we demonstrate a biologically targeted radiotherapy (BiRT) approach that can utilise multiparametric magnetic resonance imaging (mpMRI) to target hypoxia for favourable treatment outcomes. Methods: mpMRI-derived tumour biology maps, developed via a radiogenomics study, were used to generate individualised, hypoxia-targeting prostate IMRT plans using an ultra- hypofractionation schedule. The spatial distribution of mpMRI textural features associated with hypoxia-related genetic profiles was used as a surrogate of tumour hypoxia. The effectiveness of the proposed approach was assessed by quantifying the potential benefit of a general focal boost approach on tumour control probability, and also by comparing the dose to organs at risk (OARs) with hypoxia-guided focal dose escalation (DE) plans generated for five patients. Results: Applying an appropriately guided focal boost can greatly mitigate the impact of hypoxia. Statistically significant reductions in rectal and bladder dose were observed for hypoxia-targeting, biologically optimised plans compared to isoeffective focal DE plans. Conclusion: Results of this study suggest the use of mpMRI for voxel-level targeting of hypoxia, along with biological optimisation, can provide a mechanism for guiding focal DE that is considerably more efficient than application of a general, dose-based optimisation, focal boost.

18 March 2019 in Medical Physics
Verified
Journal Article
Closed access
PDF file
AKAngel Kennedy
Angel Kennedy
JDJason Dowling
Jason Dowling
PGPeter B Greer
Peter B Greer
LHLois Holloway
Lois Holloway
MJMichael G Jameson
Michael G Jameson
MEMartin Andrew Ebert
Martin Andrew Ebert

13 December 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
NYNoorazrul Yahya
Noorazrul Yahya
MEMartin Andrew Ebert
Martin Andrew Ebert
MBMax Bulsara
Max Bulsara
AHAnnette Haworth
Annette Haworth
RKRachel Kearvell
Rachel Kearvell
JDJim W Denham
Jim W Denham
To assess the impact of incremental modifications of treatment planning and delivery technique, as well as patient anatomical factors, on late gastrointestinal toxicity using data from the TROG 03.04 RADAR prostate radiotherapy trial. The RADAR trial accrued 813 external beam radiotherapy participants during 2003–2008 from 23 centres. Following review and archive to a query-able database, digital treatment plans and data describing treatment technique for 754 patients were available for analysis. Treatment demographics, together with anatomical features, were assessed using uni- and multivariate regression models against late gastrointestinal toxicity at 18-, 36- and 54-month follow-up. Regression analyses were reviewed in the context of dose-volume data for the rectum and anal canal. A multivariate analysis at 36-month follow-up shows that patients planned using a more rigorous dose calculation algorithm (DCA) was associated with a lower risk of stool frequency (OR: 0.435, CI: 0.242–0.783, corrected p = 0.04). Patients using laxative as a method of bowel preparation had higher risk of having increased stool frequency compared to patients with no dietary intervention (OR: 3.639, CI: 1.502–8.818, corrected p = 0.04). Despite higher risks of toxicities, the anorectum, anal canal and rectum dose-volume histograms (DVH) indicate patients using laxative had unremarkably different planned dose distributions. Patients planned with a more rigorous DCA had lower median DVH values between EQD23 = 15 Gy and EQD23 = 35 Gy. Planning target volume (PTV), conformity index, rectal width and prescription dose were not significant when adjusted for false discovery rate. Number of beams, beam energy, treatment beam definition, positioning orientation, rectum-PTV separation, rectal length and mean cross sectional area did not affect the risk of toxicities. The RADAR study dataset has allowed an assessment of technical modifications on gastrointestinal toxicity. A number of interesting associations were subsequently found and some factors, previously hypothesised to influence toxicity, did not demonstrate any significant impact. We recommend trial registries be encouraged to record technical modifications introduced during the trial in order for more powerful evidence to be gathered regarding the impact of the interventions.

7 June 2018 in Australasian Physics & Engineering Sciences in Medicine
Verified
Journal Article
Closed access
PDF file
AKAngel Kennedy
Angel Kennedy
JDJason Dowling
Jason Dowling
PGPeter Greer
Peter Greer
MEMartin Andrew Ebert
Martin Andrew Ebert

10 January 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ACAlessandro Cicchetti
Alessandro Cicchetti
TRTiziana Rancati
Tiziana Rancati
MEMartin Ebert
Martin Ebert
Claudio FiorinoClaudio Fiorino
Claudio Fiorino
AKAngel Kennedy
Angel Kennedy
RVRiccardo Valdagni
Riccardo Valdagni
82 Background: To develop a model for grade 3 (G3) late rectal bleeding (LRB) after radical radiotherapy (RT) for prostate cancer, in a pooled population from 2 large prospective trials: Airopros0102 (Fellin RO2014) and TROG 03.04 RADAR (Ebert IJROBP2015). Methods: Both trials included patients (pts) treated with 3DCRT at 66-80Gy, conventional fractionation. Planning data were available for all pts, G3 LRB was prospectively scored using the SOMA/LENT, with a minimum follow-up of 3 years. Rectal dose-volume histograms were reduced to Equivalent Uniform Dose (EUD) calculated with volume parameter n derived by 3 studies: n=0.06 (Rancati RO2004), n=0.05 (Rancati RO2011) and n=0.018 (Defraene IJROBP2011). EUD was inserted into multivariable logistic regression (MVL) together with clinical and treatment features. Irradiation of seminal vesicles (SV), irradiation of pelvic nodes, hormonal therapy, hypertension, previous abdominal surgery (SURG), use of anticoagulants, diabetes, cardiovascular diseases and presence of acute toxicity were considered as potential dose-modifying factors. Goodness of fit was evaluated with Hosmer Lemeshow test (HL), calibration through calibration slope and AUC was used for discrimination power. Results: 1,337 pts were available: 708 RADAR and 669 Airopros. G3 LRB was scored in 95 pts (7.1%): 62 RADAR and 33 Airopros. EUD calculated with n=0.05 was the best dosimetric predictor for G3 LRB. A 4-variable MVL model was fitted including EUD (OR=1.07 p=0.16), SV (OR=4.75 p